These results would support that P53 might not be the central mechanism underlying lung cancer cell apoptosis caused by Cym A. Additional studies to unveil how Cym A overcomes this aggressive feature (TP53 mutation) of lung cancer cells would expand its pharmaceutical potential in lung cancer therapy. This evidence concerns the gene TP53 and lung carcinoma.